Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (October 2012)
35 slides from Medical Developments International's investor presentation, October 2012
Slide 1: Medical Developments International
Medical Developments International
Slide 2: Vision
Vision Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to provide unique and innovative products to assist our customers in the management of acute and procedural pain, delivery of asthma medications, resuscitation and oxygen therapies for human and veter
Slide 3: Medical Developments International
Medical Developments International Medical Developments Australia (MDA) commenced operations in 1972 and listed as a public company in December 2003 - ASX: MVP. Our products are used in 11 countries with the list of new country registrations increasing. We have a widely recognised portfolio of brand
Slide 4: MDI Corporate Overview
MDI Corporate Overview MDI design, manufacture and distribute innovative healthcare products within Australia and Internationally. Located in Melbourne, Australia. ISO 13485, GMP compliant. Leaders in pain relief, emergency medical devices; oxygen therapies and respiratory products. Three business d
Slide 5: MDI Business Divisions
MDI Business Divisions Pharmaceutical Medical Devices Veterinary Equipment
Slide 6: MDI Pharmaceutical: Penthrox
MDI Pharmaceutical Penthrox® • Inhalational analgesic • Demonstrated safety and efficacy profile • Only manufacturer in the world • Licensed in Australia, N.Z, GCC South America, Eastern Europe & others • Manufactured in GMP compliant plant
Slide 7: Penthrox Clinical application
Penthrox Clinical application Painful procedures • Burn injuries Cosmetic Dentistry Surgery • Cutaneous excisions • Breaks, • Liquid nitrogen fractures and Military Consulting removals of skin- dislocations Rooms cancers, warts, etc • Abdomen pain • Invasive • Chest pain Ambulance Day Surgeries angi
Slide 8: Penthrox Benefits to medical professionals
Penthrox Benefits to medical professionals Rapid onset of Minimal waiting time before a painful procedure can be performed (3 minutes) and rapid pain relief when a patient is action treated for burns, trauma, etc. Inhaled self- Medical professionals can perform a procedure/ attend to an injury whils
Slide 9: Penthrox Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide Penthrox® does not effect vital signs; no clinical depression of respiration or circulation at low analgesic dosing. Self-administration, easy to use and administer. Compact and can be used in any location or situation. No risk of overdose. Single use device ensu
Slide 10: Penthrox Benefits over Morphine
Penthrox Benefits over Morphine The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there are a number of specific benefits Penthrox has over Morphine which include: Penthrox can be used on children, Morphine cannot Penthrox is not a Narcotic; opioid or dr
Slide 11: Penthrox Cost Analysis
Penthrox Cost Analysis A study performed by PharmConsult reported the following cost benefits associated with Morphine, Nitrous Oxide and Penthrox . The analysis is based on providing approximately 1 hours of pain relief. Penthrox Nitrous Oxide Morphine IV Inhalation $33.20 $49.75 $33.18
Slide 12: Penthrox Future: CSIRO manufacturing deal
Penthrox Future MDI have signed a deal with CSIRO to develop a new manufacturing technique for Penthrox If successful this will provide MDI with: 1. World leading intellectual property 2. Very significant increased production capacity 3. Very significant reduction in cost to manufacture 4. Very sign
Slide 13: Penthrox Future: Nippon Zoki and new countries
Penthrox Future MDI have signed a distribution deal with Nippon Zoki to get registered and sell Penthrox in Japan. MDI is in various stages of / working to expand into new countries in Central America, Canada, Asia, Africa, Russia.
Slide 14: Penthrox Future: new applications
Penthrox Future MDI has completed its 250 Colonoscopy trial at Royal Adelaide hospital and is developing new markets and new applications for Penthrox, including in the areas of: • Colonoscopy, • Gynaecological • Endoscopy procedures • Cosmetics • Podiatry • GP’s
Slide 15: Penthrox Future: European regulatory dossier
Penthrox Future Our aim is to create a world class regulatory dossier capable of gaining approval to sell Penthrox anywhere in the world. MDI have recently completed its 300 patient Phase III Clinical trial in Europe to gather evidence sufficient to support a regulatory approval in 1st world countri
Slide 16: MDI Medical
MDI Medical Design, assemble and test a wide range of medical devices ISO 13485 & GMP compliant assembly facilities Over 30 devices in product portfolio Focus on respiratory system and oxygen delivery Asthma management Oxygen delivery and equipment CO2 absorbers Ventilators
Slide 17: MDI Medical: Rescue and resuscitation
MDI Medical Rescue and resuscitation Our emergency medical equipment business has grown significantly since FY2011. MDI is the preferred supplier in a number of markets including – Ambulance, Non-emergency transport and Emergency First Aid Various public and private health sectors (GP clinics, hospi
Slide 18: MDI Medical: Rescue and resuscitation products
MDI Medical Rescue and resuscitation Our quality range of products is growing and consists of Oxygen Kits, regulators and manual resuscitators, Defibrillators Oxygen & CPR masks, CO2 absorbers, tourniquets
Slide 19: MDI Medical: Respiratory division
MDI Medical Respiratory division Since 1985 Medical Developments International has invested significant R&D resources to improving the delivery of Asthma and COPD medication. In 2011 MDI launched the Space Chamber Plus® and the Compact Space Chamber Plus® in the Australian and International market.
Slide 20: Respiratory division product range
MDI Medical Respiratory division MDI offers a range of innovative world leading devices that can be used to help patients manage and take control of their asthma and COPD • Space Chamber Plus® aerosol spacer • Space Chamber® re-usable • Compact Spacer Chamber Plus® • Breath-Alert® peak flow meter •
Slide 21: Space Chamber Plus tender and distributor wins
MDI Medical Respiratory division MDI Spacer Chamber Plus ® • Recently won an international tender in New Zealand to supply MDI’s range of asthma products exclusively for three years Defeated more than 10 international bidders • German distributor replaced its entire range of competitors products w
Slide 22: MDI Spacer Chamber Plus features
MDI Medical Respiratory division MDI Spacer Chamber Plus ® • New patent cross valve technology • Universal end suitable for all Metered Dose Inhalers • Compact design • Provides very low resistance for both inhalation and exhalation • Enables unrestricted and continuous breathing • Performance equiv
Slide 23: Space Chamber Plus worlds best practice
MDI Medical Respiratory division The MDI Space Chamber Plus®is worlds best practice for delivering Asthma medications References 1. Laboratory Usage of respiratory spacers and the delivered Fluticasone (Flixotide) dose of commonly used spacers available in Australia and New Zealand. 2.Output of Flut
Slide 24: Respiratory division Future: approvals
Respiratory division Future During 2012 we have obtained approval to sell our Space Chamber Plus’ and other medical devices in 1. Europe - CE Mark 2. GCC, 3. Canada 4. Parts of Asia We have lodged an application to the Food & Drug Administration in the USA sell our devices into that market We are cu
Slide 25: Respiratory division Future: European market
Respiratory division Future MDI established a European head office in June 2012 and we working with strategic business partners to develop the European Asthma market. Based on our own experience and knowledge of the market we estimate the 5 biggest markets in Europe to be as follows UK around 3.7 mi
Slide 26: MDI Veterinary
MDI Veterinary Design, assemble and test a wide range of veterinary devices Focus on anaesthesia and surgical consumables Anaesthesia Anaesthetic machines (closed circuit system) Breathing circuits Vaporisers
Slide 27: Product Development
MDI Product Development In 2011 MDI continued to invest significant energy into its product development capacity. This year we developed and launched the: Space Chamber Plus Asthma Nebulizer Space Chamber Compact Oxygen masks Regulators Pulse Oximeter Penthrox inhaler In 2012 we will continue to wor
Slide 28: Business performance: revenue
MDI Business performance MDI has experienced significant revenue growth over the past two years, driven by increased sales of Penthrox and Asthma Medical Devices 11.5 Revenue waterfall for FY 2010 to $ Sales 2012 ($m) 11.0 11,000,000 10.5 10,000,000 10.0 9.5 9,000,000 9.0 8,000,000 8.5 8.0 7,000,000
Slide 29: Business performance: profit growth
MDI Business performance MDI has experienced 210% profit growth over the past two years EBITDA Waterfall for FY 2010 to $ Net profit after tax 4.5 2012 ($m) 3,000,000 4.0 2,500,000 3.5 2,000,000 3.0 2.5 1,500,000 2.0 1,000,000 1.5 500,000 1.0 FY09 FY10 FY11 FY12 Re Ex Re Ex
Slide 30: Business performance: operating efficiencies
MDI Business performance MDI has extracted significant operating efficiencies from all aspects of the business Operating Expenses EBIT % of Sales as a % of Sales 35.0% 52.5% 30.0% 48.5% 25.0% 44.5% 20.0% 40.5% 15.0% 10.0% 36.5% 08 09 10 11 12 09 10 11 12 FY FY FY FY FY FY FY FY FY
Slide 31: Business performance: cash reserves
MDI Business performance MDI has no debt and $3.5m in cash reserves after paying $3.2 million on clinical trials and two 3 cent fully franked dividend in the last 12 months. $ Cash reserves 4,000,000 3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 - FY09 FY10 FY11 FY12
Slide 32: Business performance: share price
MDI Business performance Since April 2010 MDI share price has risen from $0.12 to $1.40 in October 2012
Slide 33: Future business performance
MDI Future business performance MDI have a number of significant business opportunities in the pipe that we can realise in the short / medium term Our Asthma medical devices are world leaders and will generate significant growth in the next 2 years Penthrox is a world leader in its category and our
Slide 34: Contact details
Contact details HEAD OFFICE Factory 6 / 56 Smith Road PO Box 21 Springvale, VIC. 3171 Sandown Village, VIC. Australia Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Slide 35: Forward looking statements
Forward looking statements This document contains certain forward looking statements relating to Medical Development International’s business, which can be identified by the use of forward looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast", "exp
Medical Developments International — Investor Presentation (October 2012) on 6ix